Argus II Prosthetic Vision
The Argus II Retinal Prosthesis is the first, and to date only, artificial visual implant commercially approved by the U.S. Food and Drug Administration (FDA). It is indicated for patients with end-stage retinitis pigmentosa (RP) in both eyes.
- PDF / 38,203,847 Bytes
- 588 Pages / 504.63 x 737.01 pts Page_size
- 82 Downloads / 164 Views
123
Macular Surgery
Andrew Chang William F. Mieler • Masahito Ohji Editors
Macular Surgery Current Practice and Trends
Editors Andrew Chang Sydney Retina Clinic and Sydney Eye Hospital Sydney NSW Australia Masahito Ohji Department of Ophthalmology Shiga University of Medical Science Shiga Japan
William F. Mieler Department of Ophthalmology and Visual Sciences The University of Illinois at Chicago Chicago IL USA
ISBN 978-981-15-7642-3 ISBN 978-981-15-7644-7 (eBook) https://doi.org/10.1007/978-981-15-7644-7 © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. 2020 This work is subject to copyright. All rights are solely and exclusively licensed by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This Springer imprint is published by the registered company Springer Nature Singapore Pte Ltd. The registered company address is: 152 Beach Road, #21-01/04 Gateway East, Singapore 189721, Singapore
Preface
Advances in technology have improved the safety, efficiency, and outcomes of macular surgery. Vitrectomy machines and cutters allow more efficient microincisional surgical approaches with safe removal of vitreous and membranes with ultra-high cutting rates. A wide suite of ergonomic disposable microsurgical instruments is available for surgeons to perform delicate surgical manoeuvres. Dyes identify tissue for accurate removal. Improved visualization during surgery with digital, 3D technology, and data connectivity leads to better surgical control. Intraoperative OCT can permit high-resolution cross-sectional imaging of delicate membranes and structures during surgery. The surgical setting, anesthesia and postoperative care of patients have resulted in more rapid healing and visual rehabilitation. The close relationship of anterior and posterior segment surgery is reflected in modern collaborative efforts with ophthalmic subspecialties. This book will
